← All trials
NCT05295459
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2022
- Primary completion
- Jan 15, 2024
- Completion date
- Jan 15, 2024
- First posted
- Mar 25, 2022
- Last posted
- Nov 30, 2022
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lyra TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.